|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's range||43.48 - 43.52|
|52-week range||43.48 - 43.52|
|Beta (5Y monthly)||0.52|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
DGAP-News: Biotest AG / Key word(s): Research Update11.10.2021 / 07:00 The issuer is solely responsible for the content of this announcement.PRESS RELEASEBiotest identifies a benefit with trimodulin in a relevant subgroup of hospitalised COVID-19 patients- Complete data set from the phase II ESsCOVID trial analysed- Post hoc subgroup analyses revealed a medical relevant benefit in hospitalised COVID-19 patients with early systemic inflammation- Biotest considers further clinical development of t
Biotest AG / Key word(s): OfferBiotest AG: Takeover Offer: Grifols S.A. to make a voluntary public takeover offer for the shares of Biotest AG17-Sep-2021 / 12:52 CET/CESTDisclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.Ad-hoc RELEASEAnnouncement according to Article 17 European Market Abuse Regulation (MAR)Takeover Offer: Grifols S.A.
MADRID (Reuters) -Spanish pharmaceuticals company Grifols proposed a 1.6 billion euro ($1.9 billion) takeover of its German rival Biotest on Friday, in a move to consolidate the plasma-based drug industry. Grifols said it had agreed with Tiancheng International Investment to buy the Hong Kong-based company's controlling stake in Biotest for 1.1 billion euros. The Barcelona-based company agreed to buy 89.88% of Biotest's ordinary shares that carry voting rights, but which represent only 44.54% of the company's capital, and a further 0.54% of capital in preferred shares that do not carry voting rights, from Hong Kong-based Tiancheng.